Why REGENXBIO Inc.’s (RGNX) Stock Is Down 5.77%
As of Wednesday, September 23, REGENXBIO Inc.’s RGNX share price has dipped by 5.77%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Commentary & Analysis
Why REGENXBIO Inc.’s (RGNX) Stock Is Up 6.58%
As of Thursday, September 17, REGENXBIO Inc.’s RGNX share price has surged by 6.58%, which has investors questioning if this is right time to sell.Michael Rose
Why REGENXBIO Inc.’s (RGNX) Stock Is Down 5.98%
As of Tuesday, September 15, REGENXBIO Inc.’s RGNX share price has dipped by 5.98%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why REGENXBIO Inc.’s (RGNX) Stock Is Up 6.39%
As of Tuesday, August 25, REGENXBIO Inc.’s RGNX share price has surged by 6.39%, which has investors questioning if this is right time to sell.Michael Rose
Why REGENXBIO Inc.’s (RGNX) Stock Is Down 24.53%
As of Monday, August 24, REGENXBIO Inc.’s RGNX share price has dipped by 24.53%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $488.5 | $257.9 | 37% |
|
| Shares Out (Mil) | 53.0 | 54.3 | 49% |
|
| Institutional Ownership | 89.8% | 92.9% | 57% |
|
| Float (Mil) | 57.2 | 41.4 | 50% |
|
| Beta | 0.93 | 0.95 | 56% |
|
| Avg Daily Volume (000s) | 1,492 | 674 | 75% |
|
| Price Change (52-week) |
(22.4%) | 51.5% | 33% |
|
| Growth | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.0% | 13.2% | 23% |
|
| Net Income (5yr) | (11.7%) | (10.1%) | 28% |
|
| EPS (5yr) | (4.7%) | 15.8% | 25 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.6%) | (15.6%) | 48% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($1.268) | ($3.519) | ($3.003) | |
| Month Ago EPS | ($1.268) | ($3.519) | ($3.003) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($1.224) | ($2.824) | ($2.575) | |
| Year/Year Chg | (394.9%) | (6.4%) | (46.7%) | |
| Financials | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $175 | $37 | 31% |
|
| Net Income (TTM) (Mil) | ($196) | ($43) | 7% |
|
| EPS (TTM) | ($3.765) | ($1.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($247) | ($32) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($43) | $2 | 21% |
|
| Long-Term Debt (Q1) (Mil) | $216 | $4 | 51% |
|
| Enterprise Value (Q1) (Mil) | $675 | $174 | 37% |
|
| Valuation | RGNX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.61 | 2.51 | 82% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (44.9%) | 68.9% | 2% |
|
| Net Margin | (112.6%) | (72.5%) | 7% |
|
| ROA | (40.6%) | (47.7%) | 14% |
|
| ROE | (137.6%) | (54.9%) | 7% |
|
| Liabilities to Assets | 81.4% | 29.1% | 76% |
|
| F-Score | 3 | 3 | 18% |
|
REGENXBIO Inc. did not pass any screens on 9/25/2026.
